Complications of intrathecal drug delivery systems

Techniques in Regional Anesthesia and Pain Management

Volumn 15, Issue 4, 2011, Pages 162-166

  Hitt, James M ^a,b   de Leon Casasola, Oscar A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer pain; Intrathecal therapy complications

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; HYDROMORPHONE; LOCAL ANESTHETIC AGENT; MORPHINE; OPIATE;

ARTICLE; BONE DENSITY; CANCER PAIN; CATHETER COMPLICATION; DRUG DELIVERY SYSTEM; FATIGUE; GRANULOMA; HUMAN; INFERTILITY; INVASIVE PROCEDURE; LETHARGY; MENINGITIS; MORTALITY; MUSCLE DISEASE; NAUSEA AND VOMITING; NEOPLASM; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; POSTDURAL PUNCTURE HEADACHE; PRURITUS; RISK; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SPINAL ANESTHESIA; URINE RETENTION; WOUND INFECTION;

EID: 83355160623     PISSN: 1084208X     EISSN: 15584534     Source Type: Journal    
DOI: 10.1053/j.trap.2011.10.001     Document Type: Article

References (22)

1. Turner J.A., Sears J.M., Loeser J.D. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007, 23:180-195.
2. Anderson V.C., Burchiel K.J., Cooke B. A prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy. Neuromodulation Technol Neural Interface 2003, 6:142-152.
3. Coffey R.J., Owens M.L., Broste S.K., et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 2009, 111:881-891.
4. Coffey R.J., Owens M.L., Broste S.K., et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med (Malden, MA) 2010, 11:1001-1009.
5. Rathmell J.P., Miller M.J. Death after initiation of intrathecal drug therapy for chronic pain: assessing risk and designing prevention. Anesthesiology 2009, 111:706-708.
6. Williams J.E., Louw G., Towlerton G. Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol Assess (Winchester, England) 2000, 4(32):iii-iv. 1-65.
7. Smith T.J., Coyne P.J. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med 2005, 8:736-742.
8. Abs R., Verhelst J., Maeyaert J., et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000, 85:2215-2222.
9. Aloisi A.M., Aurilio C., Bachiocco V., et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009, 34(suppl 1):S162-S168.
10. Katz N., Mazer N.A. The impact of opioids on the endocrine system. Clin J Pain 2009, 25:170-175.
11. Freedman J.M., Li D.K., Drasner K., et al. Transient neurologic symptoms after spinal anesthesia: an epidemiologic study of 1,863 patients. Anesthesiology 1998, 89:633-641.
12. Hampl K.F., Heinzmann-Wiedmer S., Luginbuehl I., et al. Transient neurologic symptoms after spinal anesthesia: a lower incidence with Prilocaine and bupivacaine than with lidocaine. Anesthesiology 1998, 88:629-633.
13. Keld D.B., Hein L., Dalgaard M., et al. The incidence of transient neurologic symptoms (TNS) after spinal anaesthesia in patients undergoing surgery in the supine position. Hyperbaric lidocaine 5% versus hyperbaric bupivacaine 0.5%. Acta Anaesthesiol Scand 2000, 44:285-290.
14. Nair G.S., Abrishami A., Lermitte J., et al. Systematic review of spinal anaesthesia using bupivacaine for ambulatory knee arthroscopy. Br J Anaesth 2009, 102:307-315.
15. Deer T., Krames E.S., Hassenbusch S.J., et al. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation Technol Neural Interface 2007, 10:29.
16. Bernards C.M. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006, 105:169-178.
17. Kotob F., Leon-Casasola O.D., Lema M. Intrathecal infusion rates of 1 mL/day improve narrow analgesia with infusion rates of 0.5 mL/day. American Society of Anesthesiology annual meeting 2006, A347.
18. Coffey R.J., Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002, 50:78-86.
19. Miele V.J., Price K.O., Bloomfield S., et al. A review of intrathecal morphine therapy related granulomas. Eur J Pain 2006, 10:251-261.
20. Deer T., Krames E.S., Hassenbusch S., et al. Management of intrathecal catheter-tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation Technol Neural Interface 2008, 11:77-91.
21. Johansen M.J., Satterfield W.C., Baze W.B., et al. Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications. Pain Med (Malden, MA) 2004, 5:14-25.
22. Allen J.W., Horais K.A., Tozier N.A., et al. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006, 105:590-598.